Arbutus to Participate in Upcoming Investor Conferences

VANCOUVER, British Columbia and WARMINSTER, Pa., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that the Company will be participating in the following investor conferences:

• Chardan Inaugural Gene Therapy Conference, October 10, 2017, New York, and
• Jefferies Gene Technology Summit, October 12, 2017, New York.

About ArbutusArbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com.

Contact Information

InvestorsAdam CutlerSenior Vice President, Corporate AffairsPhone: 604-419-3200 Email: [email protected]

Tiffany TolmieManager, Investor RelationsPhone: 604-419-3200 Email: [email protected]

MediaDavid SchullRusso PartnersPhone: 858-717-2310Email: [email protected]

Source: Arbutus Biopharma Corporation

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
• Kimbell Royalty Partners Closes $221.2 Million Drop Down Acquisition
• Sigma Lithium Announces Full Resumption of Mining-Industrial Operations; Signed a TAC Agreement with the State of Minas Gerais; Expects to Produce 240,000t Within 12 Months